Your browser does not support java script. Skip navigation
Loading, please wait  Loading, please wait...

Clinical Update - Westford


     Tuesday, November 7, 2017 
     Westford Regency
    219 Littleton Road, Route 110
    Westford, MA  01886
 
 
A one-day professional conference that offers pharmacists a source of CE credits, pharmacy product information, networking opportunities and gives pharmacists access to cutting edge information. Continental breakfast, lunch and afternoon refreshments will be served. 
 
Kindly note, handouts will not be available the day of the Clincal Update conference.  You may download & print, or save a PDF of the handouts to your laptop, tablet or other device. You must be registered for the conference to download the handouts directly from our website by logging in and clicking on the event. The handouts will become available 3 to 5 days before each conference.
 

 

Date: Nov 7, 2017 08:00 AM - 05:00 PM

Fee

$119.00

CE Hours

7.50

CE Units

0.750

Registration closes on Nov 06, 2017 12:00 AM

Activity Type

  • Other

Target Audience(s)

  • Pharmacists

Accreditation(s)

Accreditation Council for Pharmacy Education
American Health Resources is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education

Requirements for CE Credit

  • Participant Requirement and Statement of Credit: To receive credit, participants must fully attend each session (no partial credit will be awarded), pass in a completed attendance verification form, and using the access code provided, complete the online evaluation for each session attended. Attendance will be verified. All participants will have the opportunity to evaluate the educational sessions and presenters as well as the ability to identify their future educational needs. 
  • Pharmacists: CE credit will be automatically uploaded to CPE Monitor upon completion of the evaluation and posted to the participant’s NABP account within 72 hours where an official certificate of credit can be printed. Evaluations must be completed within 60 days of program date to receive credit.  
  • Statement of Disclosure: Disclosure will be made on the day of the program regarding any interest or affiliation a speaker may have with a supporting organization.
  • Refund Policy: A full refund will be provided only if a written request is received by American Health Resources, Inc. at least 48 hours prior to the program or if the program is cancelled. American Health Resources, Inc. reserves the right to change the presenters, topics or seminar schedules.
Only Certificates of Credit issued from CPE Monitor are valid in the US. 
CPE Monitor will not accept credits after 60 days from the session date.
 
 

Please choose a Fee Type from the Drop Down Menu Below:
I am a
 

 

 

   

The management of pain presents numerous challenges due to its subjective nature and the limitations of available treatment options. Chronic pain is now increasingly recognized as a disease which requires a multimodal approach to its management. The role of opioid analgesics for chronic pain management has been under scrutiny due numerous factors such as overprescribing, and current literature suggests that there is insufficient evidence to determine the effectiveness of long-term opioid therapy for improving chronic pain and function. Furthermore, the increased utilization of opioid analgesics for both acute and chronic pain has contributed to the growing opioid abuse epidemic within the United States. Pharmacists should have appropriate foundational knowledge of the clinical presentation of common chronic pain syndromes to assist with recommending patient-specific care plans that emphasize the role nonopioid and nonpharmacologic therapies. Additionally, pharmacists should be able to provide recommendations for chronic pain management when opioid therapy is not indicated or should be avoided (e.g., patients with opioid use disorder). For this session, attendees will be provided with interactive, patient-specific information. The session will initially highlight principles of chronic noncancer pain management with particular emphasis on the role of nonopioid and nonpharmacologic therapies. Patient cases will be presented for the attendees to determine the appropriateness of analgesic therapy for specific chronic pain diagnoses. Additional case information
will be shared with the attendees to facilitate discussion on managing chronic pain without the use of opioid analgesics. 
Application Based

Objectives

  • Compare and contrast nonopioid analgesic and nonpharmacologic therapies for the management of chronic noncancer pain.
  • Evaluate pharmacotherapeutic regimens for efficacy and safety in patients with chronic noncancer pain.
  • Given patient-specific information, design a care plan that addresses appropriate therapeutic goals for the management of chronic noncancer pain.

Speaker(s)/Author(s)

Michele Matthews, PharmD, BCACP, CPE, FASHP picture

Michele Matthews, PharmD, BCACP, CPE, FASHP
Associate Professor / Advanced Practice Pharmacist - Pain Management, Massachusetts College of Pharmacy and Health Scien

Activity Number

0280-0000-17-088-L01-P
Date: 11/07/17
Time: 08:30 AM - 10:00 AM

CE Hours

1.50
   

   

This activity is designed to educate pharmacists on new medications available for the treatment of chronic obstructive pulmonary disease (COPD) and the updated 2017 treatment guidelines.  The session will begin with a background overview of COPD including clinical presentation, pathogenesis, and diagnosis.  The presentation will focus on the recent 2017 update of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines with regards to the classification of disease severity and recommended pharmacologic management including information on many newly approved COPD medications and inhaler device types. Participants will benefit from demonstrations of the various inhaler devices so they may in turn educate patients in the pharmacy to improve self-management.
Application Based

Objectives

  • Discuss the clinical presentation and spirometry parameters used in the diagnosis of COPD.
  • Utilizing the 2017 GOLD Report, select the appropriate treatment regimen based on patient specific factors and disease assessment.
  • Implement pharmacist driven interventions which can improve health status and reduce future exacerbations.
  • Demonstrate and evaluate the proper use of various inhalation devices to support patient self-management education.

Speaker(s)/Author(s)

Timothy R. Hudd picture

Timothy R. Hudd, BS, RPh, PharmD, AE-C
MCPHS University


Brief Bio : Dr. Hudd is an Associate Professor of Pharmacy Practice at MCPHS University and has served on the faculty for the past 14 years. He delivers lectures on pulmonary related topics for several graduate and post-graduate programs and has consistently provided continuing education programs for pharmacists and clinicians around New England. In 2006, he was named “Pharmacy Practice Teacher of the Year”, “Pharmacy Practice Faculty Preceptor of the Year” in 2011 and served as President of the Massachusetts Pharmacists Association in 2012. Dr. Hudd is nationally certified as an Asthma Educator (AE-C) and is currently serving as Vice Chair for the National Asthma Educator Certification Board (NAECB) and works with several statewide asthma advocacy groups including the Massachusetts Department of Public Health (MDPH), Asthma Prevention and Control Program (APCP). Dr Hudd serves as a clinical ambulatory care faculty preceptor for advanced pharmacy students at the Primary Care of the Andovers in North Andover, MA.

Activity Number

0280-0000-17-089-L01-P
Date: 11/07/17
Time: 10:30 AM - 12:30 PM

CE Hours

2.00
   

   

This activity is designed to educate pharmacists to assist patients in managing their type 2 diabetes.  The activity will begin with an overview of the most recent guidelines from the American Diabetes Association (ADA) and American Association of Clinical Endocrinologists (AACE).  Goals and treatment algorithms for glycemic control will be compared.  Particular attention will be paid to the pharmacokinetic and pharmacodynamic profiles of basal insulins, SGLT2 inhibitors, DPP4 inhibitors, and GLP-1 receptor agonists.  Their role within the guidelines and especially combination therapy will be discussed.  An important component of the presentation will be case study review to illustrate drug selection and dosing for optimal glucose control and A1C reduction based on patient factors.  Studies have demonstrated the positive effects of pharmacist-directed medical management on glycemic control and treatment adherence.
Application Based
 
Originally offered in Cromwell , CT on October 3, 2017. If you receive credit for that activity you should not claim credit for this seminar.
 

Objectives

  • Compare, contrast and apply newly released American Diabetes Association and American Association of Clinical Endocrinologists guidelines for glycemic management in patients with type 2 diabetes.
  • Describe the pharmacokinetic and pharmacodynamic differences of the SGLT-2 inhibitors, GLP-1RAs, DPP4 inhibitors, and basal insulins, and their roles within the guidelines.
  • Evaluate current data of combination therapy, including fixed-ratio agents, based on efficacy, dosage form, and complementary actions.
  • Utilizing patient cases, formulate evidence-based treatment regimens that optimize both fasting and post-prandial glucose and A1C reduction.

Speaker(s)/Author(s)

Jennifer Goldman, PharmD, CDE, BC-ADM, FCCP picture

Jennifer Goldman, PharmD, CDE, BC-ADM, FCCP
MCPHS University


Brief Bio : Dr. Goldman has been a pharmacist for over 20 years and joined the faculty at MCPHS University in 1997. She is a Professor of Pharmacy Practice and coordinates and teaches in various therapeutics courses. She has maintained a practice in primary care and family medicine with a specialty in diabetes and cardiovascular disease since 1997 and currently takes students on rotation at Well Life Medical in Peabody, MA where she practices as a clinical pharmacist and certified diabetes educator (CDE). She is on state-wide and national organizational committees and boards including but not limited to The Massachusetts Adult Diabetes Guidelines Working Group for the Diabetes Prevention and Control Program at the Department of Public Health in Massachusetts. She has been the recipient of the Long Term Service, Trustees Award for Teaching Excellence, The Preceptor of the Year, and the Pharmacy Practice Teacher of the year at MCPHS University and has been recognized by the American Academy of Family Physicians for teaching in Family Medicine. Her primary research interests are in the areas of diabetes, cardiovascular disease and teaching.

Activity Number

0280-0000-17-081-L01-P
Date: 11/07/17
Time: 01:30 PM - 03:30 PM

CE Hours

2.00
   

   

Law
Knowledge Based

Objectives

  • Summarize USP (800) Hazardous Drugs-Handling in Health Care Settings
  • Identify areas of USP (800) effects non-sterile complex compounding
  • Give examples of best practices to handle hazardous drugs among pharmacy settings

Speaker(s)/Author(s)

Timothy D. Fensky, RPh, DPH, FACA picture

Timothy D. Fensky, RPh, DPH, FACA
Director of Pharmacy Operations, Sullivan's Health Care, Inc.


Brief Bio : Mr Fensky, a member of the Massachusetts Board of Registration in Pharmacy, is serving a three-year member term, representing District 1, on the Executive Committee. An active member of NABP, Mr Fensky served on the Association’s Task Force on Pharmacist Prescriptive Authority. A member of the Massachusetts Board of Registration in Pharmacy since 2015, Mr Fensky is currently president-elect of the Board. Mr Fensky is also the director of pharmacy operations at Sullivan’s Health Care in Roslindale, MA. He also serves on the MassHealth Drug Utilization Review Advisory Board. Further, Mr Fensky is recognized as a Full Fellow for the American College of Apothecaries. He is also an adjunct faculty member at Massachusetts College of Pharmacy and Health Sciences in Boston, MA. Mr Fensky earned his bachelor of science degree in pharmacy from Northeastern University, Bouvé College of Pharmacy and Health Sciences, and received an honorary doctor of pharmacy license from the Oklahoma State Board of Pharmacy.

Activity Number

0280-0000-17-090-L03-P
Date: 11/07/17
Time: 03:30 PM - 04:30 PM

CE Hours

1.00
   

   

Law
Knowledge Based

Objectives

  • Discuss proposed pharmacy regulations pertaining to 247 CMR.
  • Outline Board of Pharmacy Inspection tools.
  • Summarize the most recent Advisory Letters from the Board of Registration in Pharmacy.

Speaker(s)/Author(s)

Timothy D. Fensky, RPh, DPH, FACA picture

Timothy D. Fensky, RPh, DPH, FACA
Director of Pharmacy Operations, Sullivan's Health Care, Inc.


Brief Bio : Mr Fensky, a member of the Massachusetts Board of Registration in Pharmacy, is serving a three-year member term, representing District 1, on the Executive Committee. An active member of NABP, Mr Fensky served on the Association’s Task Force on Pharmacist Prescriptive Authority. A member of the Massachusetts Board of Registration in Pharmacy since 2015, Mr Fensky is currently president-elect of the Board. Mr Fensky is also the director of pharmacy operations at Sullivan’s Health Care in Roslindale, MA. He also serves on the MassHealth Drug Utilization Review Advisory Board. Further, Mr Fensky is recognized as a Full Fellow for the American College of Apothecaries. He is also an adjunct faculty member at Massachusetts College of Pharmacy and Health Sciences in Boston, MA. Mr Fensky earned his bachelor of science degree in pharmacy from Northeastern University, Bouvé College of Pharmacy and Health Sciences, and received an honorary doctor of pharmacy license from the Oklahoma State Board of Pharmacy.

Activity Number

0280-0000-17-091-L03-P
Date: 11/07/17
Time: 04:30 PM - 05:30 PM

CE Hours

1.00